1 Altered affinity to ACE2 and reduced Fc functional antibodies to SARS-CoV-2 RBD

variants

2

3

8 9

10

24

35

- 4 Authors: Ebene R Haycroft^{1*}, Samantha K Davis^{1*}, Pradhipa Ramanathan¹ Ester Lopez¹,
- 5 Ruth A Purcell¹, Li Lynn Tan^{2,7}, Phillip Pymm², Bruce D Wines^{3,4,5}, P Mark Hogarth^{3,4,5}, Adam
- 6 K Wheatley¹, Jennifer A. Juno¹, Samuel Redmond¹, Nicholas A Gheradin¹, Dale I Godfrey^{1,6},
- 7 Wai-Hong Tham^{2,7}, Kevin John Selva^{1*}, Stephen J Kent^{1,8*}, Amy W Chung^{1*}
 - * Equally contributed
- 11 Affiliations:
- 12 I Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and
- 13 Immunity, University of Melbourne, Melbourne, Victoria.
- 14 2 The Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria.
- 15 3 Immune Therapies Group, Burnet Institute, Melbourne, Victoria.
- 16 4 Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria.
- 5 Department of Immunology and Pathology, Central Clinical School, Monash University,
- 18 Melbourne, Victoria.
- 19 6Australian Research Council Centre of Excellence for Advanced Molecular Imaging,
- 20 University of Melbourne, Melbourne, Victoria.
- 21 7 Department of Medical Biology, University of Melbourne, Melbourne, Victoria.
- 22 8 Melbourne Sexual Health Centre, Department of Infectious Diseases, Central Clinical
- 23 School, Monash University, Melbourne, Victoria.
- 25 Correspondence:
- 26 Amy W Chung
- awchung@unimelb.edu.au
- 28 Stephen J Kent
- 29 skent@unimelb.edu.au
- 30 Kevin John Selva
- 31 kevin.selva@unimelb.edu.au
- 32 Department of Microbiology and Immunology,
- 33 Peter Doherty Institute for Infection and Immunity,
- 34 The University of Melbourne, Victoria 3000, Australia
- 36 **Key words:** receptor binding domain, SARS-CoV-2, antibody, variants, omicron (BA.1),
- 37 N501T, Fcy-receptors.
 - NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Conflict of interest:

The authors have declared that no conflict of interest exists.

Abstract

38

39

40 41 42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants remains a formidable challenge to worldwide public health. The receptor binding domain (RBD) of the SARS-CoV-2 spike protein is a hotspot for mutations, reflecting its critical role at the ACE2 interface during viral entry. We comprehensively investigated the impact of RBD mutations, including 6 variants of concern (VOC) or interest (Alpha, Beta, Gamma, Delta, Kappa and Omicron) and 33 common point mutations, on IgG recognition, FcγR-engagement, and ACE2-binding inhibition in plasma from BNT162b2-vaccine recipients (two-weeks following second dose) and mild-to-moderate COVID-19 convalescent subjects using our custom bead-based 39-plex array. We observed that IgG-recognition and FcyR-binding antibodies were most profoundly decreased against Beta and Omicron RBDs, as well as point mutations G446S, found in Omicron, and N501T, a key mutation found in animal adapted SARS-CoV-2 viruses. Measurement of RBD-ACE2 binding affinity via Biolayer Interferometry showed all VOC RBDs have enhanced affinity to human ACE2. Furthermore we demonstrate that human ACE2 polymorphisms, E35K (rs1348114695), K26R (rs4646116) and S19P (rs73635825), have altered binding kinetics to the RBD of VOCs potentially affecting virus-host interaction and thereby host susceptibility.

Introduction

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) — the virus responsible for causing Coronavirus Disease 2019 (COVID-19) — remains an ongoing challenge to global public health, as genomic surveillance continues to identify new mutations within the SARS-CoV-2 genome. These mutations have given rise to new variants of concern (VOCs), namely Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and most recently Omicron (B.1.1.529), each demonstrating increased transmissibility, leading to new waves of infections across the world (1,2). Mutations to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein are found across all VOC lineages and are of great interest (1). Binding of the SARS-CoV-2 RBD to angiotensin converting enzyme 2 (ACE2) receptor expressed on host cells facilitates virus entry and subsequent infection (3). As such, RBD mutations such as N501Y (found on both Beta and Omicron) which enhance the virus' binding affinity to ACE2 can boost SARS-CoV-2 infection and transmission (4). Antibodies play crucial roles in the body's immunological response against SARS-CoV-2 infection. Neutralizing antibodies target the RBD and block engagement to ACE2 receptor on host cells, thus protecting from symptomatic infection (5,6). Strong neutralizing activity against the ancestral RBD has been observed following seroconversion during SARS-CoV-2 infection, and COVID vaccination, particularly after receiving mRNA vaccines (such as Pfizer-BioNTech BNT162b2) (5). However, recent research has shown reduced neutralization capacity to VOCs, including Beta, Delta, and especially Omicron following both natural infection and vaccination (7-10). RBD mutations can result in a loss of epitope recognition by antibodies, such as the RBD mutation E484K (found in Beta and Gamma), which consequently reduces neutralizing capacity by antibodies (11). The recently emerged Omicron BA.2 harbours 16 amino acid changes at the RBD and has shown substantial escape from existing neutralizing antibodies (12). However, while RBD escape mutations can allow

SARS-CoV-2 to evade neutralization, many of the antibodies elicited to the RBD can also induce non-neutralizing activity (13,14).

Antibodies can coordinate additional functions via the crystallizable fragment (Fc) region, and growing evidence supports roles for Fc-mediated immunity in control of SARS-CoV-2 infection (15–18). Engagement of IgG with the IgG Fc gamma receptor (FcγR) on the surface of innate immune cells induces downstream effector functions, including antibody-dependent cellular phagocytosis (ADCP) (via FcγRIIa), and antibody-dependent cellular cytotoxicity (ADCC) (via FcγRIIa) (19). ADCP has been described to occur following infection and vaccination in humans to ancestral SARS-CoV-2 (14). The importance of Fc-mediated immunity has been highlighted in animal studies, where animals that received neutralising monoclonal antibodies (mAbs) with compromised Fc-regions demonstrated greater viral burdens (15,18, 20). Despite the growing role for Fc-mediated immunity in SARS-CoV-2, the impact of RBD mutations on the capacity for antibodies to recruit these functions remains minimally described. Greater understanding of antibody Fc effector functions to VOCs would allow insights into potential protective signatures that remain following vaccination or infection across emerging viral variants.

Moreover, while mutations within the RBD can alter the virus' affinity to ACE2, naturally occurring ACE-2 polymorphisms found within the human population, could also modulate host-pathogen dynamics during SARS-CoV-2 infection (21–24). Numerous human ACE2 (hACE2) protein-altering single nucleotide polymorphisms have previously been characterised with low frequency among the human population, including E35K (rs1348114695), K26R (rs4646116) and S19P (rs73635825) (22). ACE-2 polymorphisms which alter expression of ACE-2 on cells have also been predicted to affect affinity to RBD (21,22,24). The ACE2 polymorphisms S19P and K26R are predicted to confer increased susceptibility to infection due to increased binding affinity to ancestral SARS-CoV-2 RBD and

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

full spike, as well as VOCS Alpha, Beta, Gamma (24–26). In contrast, the ACE2 polymorphism E35K has decreased binding to RBD constituting a more protective phenotype (24–26). However, the impact of RBD mutations of recently emerged VOCs, namely Delta and Omicron, on the affinity to these protein-altering ACE2 polymorphisms are yet to be investigated. With the rise of VOCs, it remains crucial to understand the impact of RBD-mutations on key facets of host-interactions that may contribute to SARS-CoV-2 infection dynamics. Here, our study comprehensively measures the impact of 39-RBDs, including VOCs Beta, Omicron, and Delta, as well as common single point mutations, on the impact of IgG binding and ACE2 inhibition from the plasma of BNT162b2-vaccine recipients and mild-to-moderate convalescent donors using multiplexing. Our results show a loss of IgG -recognition against the RBD of VOCs, notably Omicron and Beta, and numerous single point mutations, including G446S and N501T. Importantly, this reduction translates to a loss of FcyR-binding antibodies and was validated using ADCP-assays, which demonstrate the capacity to induce Fc-effector functions are compromised against the RBD mutations found in VOCs. We also provide evidence that affinity between ACE2 and RBD influences the potential for antibodies to block ACE2-binding, using a surrogate in-vitro neutralisation assay. By using biolayer interferometry, we demonstrate that mutations found in VOCs and human ACE2 polymorphisms (E35K, K26R, S19P), alter the affinity and binding kinetics between RBD and ACE2, which may ultimately influence an individual's susceptibility to COVID-19 infection.

Methods

Human Samples and Ethics Statement

Convalescent COVID-19 plasma samples were collected from individuals with mild-to-moderate disease as previously described (n=15) (27). Briefly, these samples were collected early-2020 (March to May) during the first wave in Australia and were likely infected with the ancestral strain. Vaccine plasma samples were obtained from individuals prior to vaccination (baseline) and two-weeks following second dose with Pfizer-BioNTech (BNT162b2) (n=16) as previously described (28). Participants characteristics for convalescent COVID-19 subjects and vaccine recipients are detailed in Table 1. Whole blood was collected into sodium heparin anticoagulant coated vacutainers before plasma was collected and stored at -80°C. Study protocols were approved by the University of Melbourne Human Research Ethics Committee (#2056689).

Proteins

SARS-CoV-2 antigens of the ancestral wild-type virus (B.1) are as follows: spike S1 (Sino Biological; 40591-V08H), spike S2 (ACRO Biosystems; S2N-C52H5), nucleoprotein (ACRO Biosystems; NUN-C5227) and spike trimer (provided by Adam Wheatley) (29). Influenza H1Cal2009 (Sino Biological; 11085-V08H) and SIVgp120 (Sino Biological; 40415-V08H) were used as positive and negative controls respectively (See Supplementary Table 1).

RBD Recombinant Proteins

SARS-CoV-2 RBD recombinant proteins, listed in Supplementary Table 2, were synthesized as previously detailed (30). Briefly, the sequences (obtained from GISAID surveillance repository) of the ancestral strain and RBD mutants were subcloned into pcDNA3.4 vectors by GenScript Corporation and subsequently expressed in Expi293 HEK

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

cells (27). All RBD proteins underwent a two-step purification process, initially through HisTrap Excel HP columns (Cytiva) followed by a Superdex 75 Increase 10/300 pg gel filtration column platform (GE Healthcare), before protein concentrations were determined (absorbance measurement wavelength at 280nm). To study Omicron responses, ancestral WT RBD and Omicron BA.2 RBD were purchased from Sino Biological. hACE2 Synthesis of truncated human ACE2 (residues 19-613 with a C-terminal AviTag and 6xHis-tag) was conducted as previously described (30). Targeted biotinylation was then performed using BirA enzyme prior to purification by strong anion exchange (Cytiva)(30). **Multiplex Platform** Coupling of protein antigens to beads Custom Luminex multiplex arrays were established to study SARS-CoV-2 antibody responses in accordance with previously established protocols (31). A complete list of protein antigen quantities-to-bead ratio for the SARS-CoV-2-specific multiplex assay and ACE2inhibition assay can be found in Supplementary Table 1 and Supplementary Table 2 respectively. SARS-CoV-2-specific multiplex assay To characterize antibody responses across plasma samples, we utilized a broad panel of SARS-CoV-2 antigen coupled beads (see Supplementary Figure 1) in a Luminex multiplex array as previously described (Selva et al., 2021). Briefly, 1000 beads/bead region diluted in PBS containing 0.1% BSA (incubation buffer) were added to each well (in a total of 20µl volume/well) in 384-well plates (Greiner Bio-One; 781906), followed by addition of 20µl/well of plasma diluted at a single concentration (1:100 in PBS). Plates were incubated on a plate-shaker overnight at 4°C before wells were washed with PBS 0.05% Tween-20 (PBST). Phycoerythrin (PE)-conjugated mouse anti-human antibodies that detect isotype (*Pan*-IgG, IgA1; Southern Biotech; 9040-09; 9130-09), or, biotinylated IgM (MabTech; mAb MT22), or, biotinylated Fc-receptors (FcγRIIa-H131, FcγRIIIa-V158) (kindly provided by Bruce Wines and Mark Hogarth (32)) were diluted to 1.3μg/ml and added at 25μl volume/well before 2hrs at room temperature on a plate shaker. For biotinylated detectors, plates were followed with an additional PBST wash, and incubated with streptavidin-PE (Invitrogen; S866) at room temperature for 1hr. Plates were then washed with PBST and each well resuspended in 50μl of sheath fluid. The level of PE-signal associated with each bead region in each well, reported as median fluorescence intensity (MFI), was determined by a Flexmap3D Luminex platform. Each sample was run in duplicate.

ACE2-inhibition assay

We employed a recently established surrogate neutralisation assay capable of simultaneously measuring the neutralising capacity of antibodies against multiple RBD variants (See Supplementary Table 2), following a slightly modified version of the protocol (30). Briefly, 700 beads/bead region diluted in incubation buffer were added to each well (in a total of 20µl volume/well) in 384-well plates, followed by application of plasma, prepared as an 8-point serial dilution beginning at 1:5 in PBS for each sample (20µl/well). Plates were covered and incubated on plate shaker for 1hr, and then 20µl/well of biotinylated-hACE2 diluted to 25µg/ml was added, followed again by 1hr shaking at room temperature. Plates were then washed with PBST and incubated with 40µl of streptavidin-PE (Invitrogen; S866) diluted to 4ug/ml in incubation buffer on a plate shaker for 1hr. Following incubation, plates were incubated for an additional 1hr with 10µl/well of R-PE Biotin-XX conjugate (Thermo Fisher

Scientific; P811) diluted to 10μg/ml before washing with PBST and resuspension in 50μl of sheath fluid. Flexmap3D Luminex platform was used for acquisition of samples and reported as MFI for each bead region used. Plates were run in duplicate.

For wells used in the detection of isotype (IgG, IgM, IgA) and FcR-binding features of RBD-specific antibodies, 20ul/well of incubation buffer-*only* was added in replacement of diluted-biotinylated hACE2. Plates were then washed with PBST and incubated with respective detectors in methods described above.

Biolayer interferometry (BLI)

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

The WT ACE-2 – RBD variant binding kinetics Bio-layer interferometry (BLI) was performed on the Octet Red instrument (FortéBio) as previously described (30). Briefly, Streptavidin Biosensors (FortéBio) hydrated in HBS-EP buffer ((0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, and 0.005% v/v Surfactant P20, pH 7.4 (GE Healthcare)) for 20 minutes were programmed to perform loading of biotinylated ACE-2 at 3µg/ml. Once the ACE-2 binding response reached a threshold of 1.6nm, the sensors were equilibrated in buffer-only wells for 120 seconds (baseline signal). The ACE-2 loaded sensors then captured respective RBD variants at concentrations ranging from 100nM to 6.25nM (diluted via 2-fold serial dilution) for 150s (association phase). Sensors were finally immersed in buffer-only wells for 360s to record the dissociation signal. Curve fitting was performed using a global fit 1:1 langmuir binding model using Octet Data Analysis software v12.0.2.3 (FortéBio), and baseline drift was corrected by reference subtracting the shift of an ACE2-loaded sensor immersed in kinetic buffer only. Mean kinetic constant values from 2 independent experiments were determined, with all binding curves matching the theoretical fit with an r2 value of more than 0.99. The complex t1/2 in seconds was calculated using the formula: t1/2 = 1n2/kdis = approximately0.69/ koff.

BLI for measuring ACE-2 polymorphism binding affinity to RBD variants utilized the same protocol as above. The difference is only at the association phase, where sensors loaded with respective ACE-2 variants at 3ug/ml concentration were immersed into wells with RBD variants at a single concentration of 100nM for 150s. Baseline, loading and dissociation phases were as described above. A local fitting 1:1 binding model was used to calculate the curve fit and kinetic constants.

Both assays were performed in 96-well plates (Greiner Bio-One™ Polypropylene 96-Well F-Bottom Microplates, black (Interpath 655209) at 1000rpm and 30°C.

Bead-based ADCP duplex assay

To assay the capacity for vaccinee plasma to mediate ADCP to SARS-CoV-2 wild type and to VOC's, a competitive, sample sparing duplex ADCP assay was adapted from previously described assays (14,33,34). SARS-CoV-2 RBD wild type (WT) and SARS-CoV-2 RBD derived from the VOC Beta (B.1.351) were biotinylated using EZ-Link Sulfo-NHS-LC biotinylation kit (Thermo Scientific) with 20mmol excess according to manufacturer's instructions and buffer exchanged using 30kda Amicon centrifugal filters (EMD millipore) to remove free biotin. Red or yellow-green 1µm fluorescent NeutrAvidin Fluospheres beads (Invitrogen) were coupled overnight at 4°C to RBD WT and RBD Beta respectively (1ul beads:3ug antigen). Coupled beads were washed thrice with 2% BSA/PBS to remove excess antigen, diluted 1:100 and combined to form a bead cocktail. 10ul of bead cocktail (9x10⁵ beads) was added to each well in a 96-well U-bottom plate with titrations of baseline and vaccinee plasma (1:100-1:777600) and incubated for 2 hours at 37°C. THP-1 monocytes (100,000 cells/well) were added to opsonized beads and incubated for 16 hours under cell culture conditions. Cells were fixed with 2% formaldehyde and acquired by flow cytometry on a BD LSR Fortessa with a HTS. The data was analyzed using FlowJo 10.8.1 (See

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

Supplementary Figure 1 for gating strategy) and phagocytosis scores were calculated for each bead type (RBD WT and RBD Beta) as previously described using the formula: [%beadpositive cells × mean fluorescent intensity] (35). To account for non-specific uptake of Sconjugated beads, the phagocytosis scores for each plasma sample were subtracted with that of the "no plasma" control. ED50's was calculated for each sample and assays were performed in duplicate. **Statistics** Systems Serology (LASSO PCA) Antibody features were selected using a least absolute shrinkage and selection operator (LASSO) reduction method as previously described using MATLAB version 9.6 (including machine learning and statistical toolbox) (The MathWorks, Inc., Natick, MA) and Eigenvector PLS toolbox (Eigenvector, Manson, WA) (36). In brief, data was first processed by rightshifting (to remove negative values) and log transformation (using equation $log_{10}(x + 1)$) prior to being normalized using z-scoring. LASSO feature reduction was then employed on z-scored data and performed 1,000-times with 10-fold cross validation. Using LASSO-selected features, unsupervised principal component analysis (PCA) was then performed. Data Analysis Prism GraphPad version 9.0.2 (GraphPad Software, San Diego, CA) were used to develop graphs and perform statistical analysis as described in respective figure legends.

Results

Greater IgG and $Fc\gamma R$ -binding antibodies to ancestral SARS-CoV-2 spike and RBD in BNT162b2 recipients compared to mild-to-moderate convalescence

Sixteen individuals vaccinated with BNT162b2 had plasma samples drawn before vaccination (baseline) and two weeks (median: 13 days; IQR: 0.75 days) following the second dose (Table 1). We also studied plasma from fifteen convalescent individuals (median: 38 days post symptom onset; IQR: 10.5 days) with mild-to-moderate COVID-19 disease. Importantly, convalescent samples were collected during the first wave of the pandemic (between March 2020 and May 2020 in Victoria, Australia), providing an opportunity to study responses in individuals infected by pre-VOC ancestral viruses that harbor less phylogenic deviation from the ancestral reference strain used in the BNT162b2 mRNA vaccine.

First, we characterized the plasma humoral profile to SARS-CoV-2 proteins (NP, RBD, S1, Trimer Spike) found in the ancestral wild-type virus. Using a SARS-CoV-2 multiplex bead assay, we measured antibody isotype (IgG, IgA1, IgM), and subclass (IgG1, IgG2, IgG3, IgG4) levels, as well as the capacity for antigen-specific antibodies to engage soluble FcγRIIa and FcγRIIIa-dimer constructs, which mimic the surface of innate immune cells and are a proxy readout for ADCP and ADCC activity respectively (19). Robust antibody responses to NP were uniquely associated with convalescent COVID-19 individuals, indicating no prior infection in the BNT162b2-vaccinees (Figure 1A; Supplementary Figure 2). Convalescent and BNT162b2-vaccinees both elicited elevated levels of IgG to spike antigens, however BNT162b2-vaccinees demonstrated significantly greater responses in comparison to convalescent individuals which displayed more heterogenous responses (S1, 3.8-fold higher; trimer, 1,6-fold higher; RBD, 3.5-fold higher), (Figure 1B-D; Supplementary Figure 2). Consistent with this, plasma from BNT162b2-vaccinees showed significantly higher FcγRIIa and FcγRIIIa-dimer binding levels by anti-spike antibodies than mild-to-moderate convalescent patients (Figure 1B, D;

Supplementary Figure 2). We then used systems serology to broadly examine this repertoire of antibody responses and observed with principal component analysis (PCA) that the baseline, BNT162b2 (2-weeks post dose two), and convalescent (mild-to-moderate) subjects naturally separated into three distinct groups based on their antibody signatures (Figure 1E). A total of fifteen antibody features, selected using a LASSO (least absolute shrinkage and selection operator) feature-reduction tool, were key contributors to the differentiation between groups (Figure 1F). This analysis highlights that BNT162b2-vaccination induces more robust anti-ancestral spike IgG responses with greater $Fc\gamma R$ -binding capacity, in comparison to mild-to-moderate convalescent donors.

Reduced IgG binding antibodies to SARS-CoV-2 RBD variants, but not always concordant to loss in ACE2 inhibition

The RBD of the spike protein is a mutational hotspot for SARS-CoV-2. Because of its position at the ACE2 interface, mutations in the RBD can alter ACE2 affinity as well as result in the loss of epitopes for antibodies (2,37,38). Thus, to characterize the impact of RBD-mutations on plasma IgG binding in our convalescent and BNT162b2 donors, we generated a custom panel of 39 RBDs, including RBDs of 33-common point mutations, 5 variants of concern/interest (Beta, Delta, Gamma, Kappa, and Omicron) and the ancestral RBD, and measured antibody responses using multiplex. Higher levels of IgG binding responses (larger reciprocal ED₅₀ values) were observed in BNT162b2-vacinees compared to convalescent individuals across all RBDs assessed (Figure 2A, E), consistent with our previous observation that BNT162b2 elicits more robust anti-spike IgG responses. Despite the overall greater levels of IgG in vaccinees, significantly reduced IgG recognition was observed against the VOCs Beta (7.1-fold reduction, p < 0.0001)) and Gamma (15.5-fold reduction, p < 0.0001) by BNT162b2 plasma in comparison to the ancestral RBD (Figure 2C; Supplementary Table 5).

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

Drop in IgG binding was also observed with Omicron (BA.2) (2.9-fold reduction, p < 0.0001) (Figure 2E). Furthermore, significant decreases in IgG recognition to various point mutations, including G446S (5.4-fold reduction, p < 0.0001) found in Omicron, E484K (5.9-fold reduction, p < 0.0001) found in Gamma and Beta, as well as F490S (5.4-fold reduction, p < 0.0001) and N501T (6.8-fold reduction, p < 0.0001) (Figure 2C; Supplementary Table 5). This data highlights the influence of particular point mutations on recognition of the RBD by IgG antibodies. Since the RBD is a dominant target for neutralizing antibodies, we next considered the impact of these RBD-variants on blocking ACE2 binding, using a surrogate neutralization assay. Using a previously established *in vitro* ACE2 inhibition assay, we measured the capacity for BNT162b2 and convalescent plasma to block hACE2 binding in a competitive format (30). Overall, the capacity for BNT162b2 plasma to block ACE2 binding was greater (larger reciprocal ID₅₀ values) in comparison to convalescent plasma across all 39-RBDs (Figure 2B, F). Consistent with the loss of IgG binding, we observed decreased ACE2 inhibition to all assessed VOC, with a significant decrease observed for Beta (3.6-fold reduction) and Gamma (5.1-fold reduction), though this reduction was notably smaller than that for IgG binding (Figure 2C). A substantial drop in ACE2 inhibition was observed with Omicron (BA.2) (26fold reduction; p < 0.0001) highlighting the evasive nature of this variant (Figure 2F). On the other hand, most of the RBD point mutations which displayed reduced IgG binding did not necessarily translate to a significant drop in ACE2 inhibition (Figure 2C, D). While a decrease in IgG binding was observed for the RBD mutations G446S and N501T, the loss in ACE2 inhibition observed was much weaker (G446S=1.6-fold reduction, p = ns; N501T=2.0-foldreduction, p = 0.0013) (Figure 2D; Supplementary Table 3). A 1.7-fold-reduction (p = 0.04) in ACE2-blocking was also observed for L452R, despite having comparable IgG binding (p = ns) to the ancestral RBD. Furthermore, the RBD mutation N501Y, the prime mutation found in the RBD Alpha-VOC, demonstrated no significant decrease in IgG binding (1.6-fold reduction, p > 0.99) but showed a significant drop in capacity to block ACE2 from binding (5.4-fold reduction, p < 0.0001) (Figure 2C, D; Supplementary Table 5). Together, this data highlights the influence of naturally occurring RBD-mutations on the potential for polyclonal antibodies to recognize and block ACE2 binding.

SARS-CoV-2 VOC RBDs have improved affinity to WT-hACE2

Mutations within the RBD also have the potential to modulate affinity to hACE2 (2,4,38,39). Hence, we next characterized the binding affinity of wild type (WT)-ACE2 to VOC RBDs, as well as a subset of single-point mutations, using biolayer interferometry (Figure 3; Supplementary Figure 3). We found all VOC RBDs assessed demonstrated elevated binding affinity to WT-ACE2 in comparison to ancestral-RBD (K_d: 29.4 nM; t_{1/2}: 83.6 s) (Figure 3). These included Beta (K_d: 14.6 nM; t_{1/2}: 164.83), Gamma (K_d: 15.0 nM; t_{1/2}: 214.82 s) and Delta (K_d: 21.5 nM; t_{1/2}: 143.77 s). Omicron (BA.2) demonstrated a 2.6-fold increase in binding (K_d: 11 nM; t_{1/2}: 161.75 s), compared to ancestral-RBD (Figure 3). Together, these data reiterate how these mutations in the RBD, given its position at the ACE2-interface, can potentially improve viral fitness by enhancing affinity to ACE2. Furthermore, these data suggest that the RBD mutations observed in Beta and Gamma not only significantly reduced IgG binding, but also compounded with stronger ACE2 affinity to give the largest drops in ACE2 inhibition.

Previously, we and others have shown single-point mutations in RBD (such as N501Y found in Alpha, Beta, Gamma and Omicron) can enhance affinity to ACE2 (4.5-fold increase; K_d : 6.5 nM; $t_{1.2}$: 329.1 s, Figure 3B) (4,30,37). With N501Y, we observed a reduced capacity for antibodies to neutralize, despite no loss in total-IgG (Figure 2). Similar to N501Y, here we observed using BLI that while L452R did not differ greatly from the ancestral RBD in total IgG binding, it exhibited a stronger affinity (K_d : 27.36 nM; $t_{1.2}$: 126.4 s), which in turn could

explain the drop in plasma-driven ACE2 inhibition (Supplementary Figure 3; Supplementary Table 4). Likewise, using BLI, we observed that N501T had improved binding affinity (K_D : 11.05 nM; $t_{1.2}$: 217.8 s) as compared to the ancestral RBD (Supplementary Figure 3; Supplementary Table 4). As such, the combination of poorer IgG binding due loss of epitope and stronger ACE2 affinity for N501T could further impeded ACE2 inhibition by plasma samples. Together, these results suggest that beyond antibody recognition, affinity interactions between RBD and ACE2 exert another layer of influence on the potential for antibodies to effectively block ACE2-binding and achieve neutralization.

hACE2 polymorphisms alter affinity to SARS-CoV-2 RBD variants

Several ACE2 polymorphisms are present at low frequency within the human population, with certain alleles more prevalent in different populations (Supplementary Table 6). In particular, K26R has been observed at low frequencies across most populations, whereas low frequencies of S19P is predominantly detected within African/African American populations (0.3%) (21,23). Previous work has shown these polymorphisms confer altered affinity to ancestral RBD, however the binding kinetics to emerged VOC RBD, especially Delta and Omicron, has yet to be described. Here we assessed the binding profiles of three low frequency ACE2 polymorphisms (E35K, K26R and S19P) to 5 VOC RBDs (Alpha, Beta, Delta, Gamma, Omicron (BA.2)) and ancestral RBD using biolayer interferometry (BLI). We found that the polymorphism S19P (K_D: 14.38 nM) and K26R (K_D: 20.0) demonstrated a 2.04-fold and 1.47 fold increase in binding affinity respectively to ancestral-RBD when compared to WT ACE2 (K_D: 28.99 nM) (Figure 4, Supplementary Table 5). Furthermore, this enhanced affinity of the S19P and K26R polymorphisms remains overall elevated against the RBD's of Beta (K_D: S19P=10.51 nM, K26R=17.46 nM), Omicron (BA.2) (K_D: S19P=4.97 nM, K26R=5.18 nM) and Delta (K_D: S19P= 8.56, K26R=13.47) (Figure 4, Supplementary Table 5). These data

suggest that individuals who harbor S19P or K26R ACE2 polymorphisms may have greater susceptibility to infection by SARS-CoV-2 due to increased ACE2 affinity. Contrastingly, ACE2 polymorphism E35K demonstrated weaker binding when compared to ancestral-RBD (K_D: 36.63 nM), Omicron (BA.2) (K_d: 18.50 nM) and Delta (K_d: 43.34 nM), suggesting that individuals harboring the E35K ACE2 polymorphism may demonstrate a more protective phenotype due to reduced ACE2 affinity for RBD (Figure 4; Supplementary Table 5). Together, these data suggests that ACE2 polymorphisms, though low in frequency, can modulate binding to ACE2, and by extension may change an individual's susceptibility to infection.

Reduced FcyR-binding antibodies to RBD variants

Several previous studies have highlighted an importance for Fc-effector functions during SARS-CoV-2 infection (14,15,17,18,20). Given the observed loss of IgG to certain RBD-variants, we next investigated the impact these mutations conferred on the capacity to for anti-RBD antibodies to engage our Fc γ RIIa and Fc γ RIIIa-dimer constructs, a surrogate measure for ADCP and ADCC activity respectively. We used our multiplex panel of 39-RBD to address the impact of these mutations on FcR-binding antibodies as compared to the ancestral RBD. Consistent with our previous observation to total-IgG levels, BNT162b2 vaccinee plasma had a significantly greater capacity (higher reciprocal ED50 vales) to engage both our Fc γ RIIa and Fc γ RIIIa-dimer constructs across all variants, in comparison to convalescent plasma (Figure 5A,B). Compared to ancestral-RBD, VOC Beta and Gamma demonstrated a significant decrease in anti-RBD Fc γ RIIa (9.8 and 14.9-fold-reduction respectively; p < 0.0001) and Fc γ RIIIa-dimer binding antibodies (8.4, and 7.2-fold-reduction respectively; p < 0.0001) (Figure 5C, D). Likewise, a drop was observed with Omicron BA.2 to both Fc γ RIIa and Fc γ RIIIa (3.1 and 3.7-fold reduction respectively; p < 0.0001) (Figure 5E, F). Altogether, our

data suggests that the capacity to recruit Fc-effector functions is compromised by mutations found in VOCs (Figure 5; Supplementary Table 3). Furthermore, we observed that single-point mutations with poorer IgG binding, such as N501T and G446S, displayed a significant reduction in Fc γ R-binding as well (Fc γ RIIa: 6.2-, 5.0-fold reduction respectively; Fc γ RIIIa 5.5-, 2.1-fold reduction respectively) (P < 0.0001) (Figure 5C, D; Supplementary Table 3). These results are consistent with the loss of IgG-recognition we observed to our panel of variants (Figure 2). To confirm our findings using the surrogate Fc γ R dimers, we next measured the capacity for BNT162b2 plasma to induced ADCP using a duplex bead-based assay with a THP-1 monocyte cell line. Fc γ RIIa reciprocal ED50 values correlated well to phagocytosis levels of ancestral-RBD by THP-1 monocytes (spearman r = 0.59, p = 0.017), as well as the RBD of Beta (spearman r = 0.52, p = 0.4) (Figure 5G, H). We observed a significant decrease in ADCP activity against ancestral vs Beta RBD (p = 0.0026), supporting the mutations found in VOCs are detrimental to Fc γ R-binding antibodies (Figure 5I).

Discussion

The emergence of SARS-CoV-2 variants has led to new waves of infection across the globe, with the RBD of SARS-CoV-2 spike being a key site for escape mutations (1,40). Here, we showed reduced recognition of RBD-variants by IgG plasma antibodies from both BNT162b2 and convalescent-subjects, with profound loss against VOCs Beta, Gamma, and more recent Omicron, indicative of evolutionary immune escape. Using our surrogate RBD-ACE2 multiplex bead assay, we showed that the drop in IgG-binding against VOCs corresponded to a reduction in neutralization capacity, consistent with others (8,41–43). Furthermore, in line with loss of IgG binding, we also found a decrease in anti-RBD Fc γ R -binding antibodies against variants, suggesting Fc γ R functions were not well retained against VOC-RBDs. Interestingly, Bartsch et al., also went on to show that Fc γ R-functions against the

full-VOC spike are less drastically impacted by mutations, likely reflecting the greater number of conserved epitopes harbored on the full-spike that can be targeted by both neutralizing and non-neutralizing antibodies (44).

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

Consistent with recent literature, all VOC-RBDs (Beta, Gamma, Delta, Omicron (BA.2) bind WT-ACE2 with enhanced affinity, reflecting evolutionary mutations that enhance viral entry and transmission (26,39). Moreover, a key finding in our study was that human ACE2 polymorphisms, whilst found in low frequencies, also demonstrated distinct variation in affinity to the RBD of VOCs. Here, we provided first insights into the binding affinity of VOC-RBDs, notably Delta and Omicron, to several ACE2 N-terminal polymorphisms – the site for RBD docking. K26R (rs4646116), – the second most frequent human ACE2 polymorphism (0.4% allele frequency), displayed enhanced binding affinity to ancestral-RBD, and VOCs, Alpha, Delta, while maintaining similar affinity to Omicron (24,45). S19P which is predominantly observed within African/African America populations (0.3%) also showed enhanced affinity to ancestral RBD, along with all tested VOC (Alpha, Beta, Delta, and Omicron) (24,45). These stronger binding affinities to VOCs RBDs may pre-dispose subsets of individuals harboring these polymorphisms to become more susceptible to breakthrough infections by SARS-CoV-2 variants (21,22,24,45-47). Intriguingly, K26R (rs4646116)demonstrated slightly weaker binding to RBD-Beta. E35K (rs1348114695, which has been predominantly detected at very low frequencies (0.01%) in East Asian populations) also had decreased affinity to ancestral RBD and more importantly demonstrated an even greater loss in binding affinity to VOC RBDs, particularly Beta, Delta, and Omicron, which may confer some level of natural protection against breakthrough infections by these variants. Our work suggests that large genetic linkage studies together with VOC infection and severity data could be informative.

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

Assessing single point mutations found in the RBD can provide valuable insights into the importance of these mutations on overall viral fitness. Here, we found numerous point mutations imparted little impact on anti-RBD IgG-recognition as well as FcyR-binding engagement. This was observed for RBD point mutations L452R and T478K (both found in Delta), which may account for the limited reduction in total IgG binding and FcyR-binding observed against Delta RBD. However, we noted that L452R-RBD had a longer binding halflife to WT-ACE2, which could contribute to the observed loss of ACE2 neutralization. Indeed, it has been described that L452R increases SARS-CoV-2 infectivity and fusogenicity, thus may confer an evolutionary advantage previously observed with Delta and more recently the Omicron sublineages BA.4 and BA.5 (48). On the other hand, certain point mutations, such as G446S (found in Omicron), G446V, S477I and S477R conferred reduced recognition by IgG. Therefore, suggesting mutations at amino acid position 446 and 477 are advantageous for viral immune escape, which is further reinforced by loss of FcyR-binding. Interestingly, while S477N (found in Omicron) also resulted in a drop in total IgG binding, it was less disruptive to FcyR-dimer engagement than both S477I and S477R (24,25). We also observed the largest fall in total IgG binding against N501T, which displayed increased ACE2 affinity and longer binding half-life resulting in a significant loss in neutralization. While N501T had weaker ACE2-binding affinity compared to N501Y – a key RBD mutation found in Delta, Beta and now Omicron – the loss in FcyR-binding was more profound with N501T, corresponding to the drastic reduction in total IgG binding. This is of growing concern for zoonotic transmission as N501T is a dominant RBD mutation identified in SARS-CoV-2-infected minks, ferrets, and deer (49–51). Several future studies are suggested by our work. While our cohort of BNT162b2individuals received two-doses of vaccine, the current approved regimen is now expanded to three-doses in Australia and many other countries. Three doses enhance antibody responses to VOCs overall and it will be important to dissect particular mutations for their impact on improved RBD-specific antibody responses. It is also unclear how our finding observed with BNT162b2 -vaccination will translate to other SARS-CoV-2 vaccines with more or less potent responses (such as mRNA-1273, adenoviral vectors, inactivated viruses, and protein subunit vaccines). Furthermore, neutralizing antibody responses elicited from current Omicron BA.2 infections have been shown to differ from that of earlier waves (Omicron BA.1 and Delta) and this will also likely impact the specificity of RBD responses (52). Lastly, due to resource constraints, we opted to use commercially available Omicron BA.2 and WT RBD to study responses against Omicron. The subtle variations between our in-house and the commercially available RBD expression templates led to noticeable differences in multiplex assay sensitivity.

Overall, our data show that RBD mutations, both common point mutations as well as combinations of mutations in VOCs, not only have an impact on affinity to receptor ACE2, but

also IgG-binding and the Fc functional antibody response, thereby providing an important site

Acknowledgements

for viral adaptions.

This study was supported by the Victorian Government and Medical Research Future Fund (MRFF) GNT2002073 (to A.K.W, P.M.H., W.-H.T., D.I.G., S.J.K., and A.W.C.), GNT2005544 (to A.K.W., J.A.J., D.I.G., S.J.K., and A.W.C.), the Paul Ramsay Foundation (A.K.W., D.I.G., S.J.K. and A.W.C.). A.K.W, J.A.J., D.I.G., W.-H.T., S.J.K. and A.W.C. are supported by NHMRC fellowships. W-H.T. is a Howard Hughes Medical Institute–Wellcome Trust International Research Scholar (208693/Z/17/Z). N.A.G. is supported by an ARC DECRA fellowship.

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

Authors contributions: E.R.H., S.K.D., K.J.S., and A.W.C drafted the original manuscript. E.R.H, S.K.D., P.R., E.L., K.J.S. and A.W.C. designed experimental protocols. E.R.H, S.K.D., P.R., E.L., R.A.P., K.J.S. performed experiments and analyzed data. L.T., P.P, B.D.W., P.M.H., A.K.W, S.R., N.A.G., D.I.G. and W-H.T contributed unique reagents. J.A.J. and S.J.K. contributed unique samples. K.J.S., S.J.K. and A.W.C. conceived and supervised the study. All authors reviewed the manuscript. **Competing interests:** The authors declare no competing interests. Data and materials availability: All relevant data is available in the manuscript or in the supplementary materials. Any additional supporting data can be provided upon request. **Figure Legends** Figure 1. SARS-CoV-2 serological signatures distinguish BNT162b2 vaccinated, convalescent, and baseline individuals. Plasma humoral responses were profiled via multiplex for convalescent mild/moderate COVID-19 patients (green square; median 38 days post symptom onset; n = 15) and BNT162b2-vaccinated individuals at baseline (purple triangle; n = 16) and two-weeks following second dose (blue circle; n = 16). Radar plots show the median MFI (median fluorescence intensity) value of each antibody signature (IgG, IgA, IgM, IgG1-IgG4, Fc\u03c9Rdimer binding) to NP (A), trimeric spike (B), S1 (C), and RBD (D). The median MFI for each feature was normalised using z-scoring prior to plotting. (E) Unsupervised principal component analysis comparing convalescent COVID-19 individuals and BNT162b2-vaccinated

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

individuals at baseline and two-weeks following second dose of 15-SARS-CoV2 antibody features selected by a dimensionality reduction method (LASSO). 95% confidence intervals for each group are depicted by a coloured eclipse. (F) PC1 and PC2 loadings of LASSO selected features for NP (yellow triangle), trimeric spike (red circle), spike subunit-1 (S1) (orange inverted triangle) and receptor binding domain (RBD) (brown square) of the PCA. Figure 2. IgG-binding and hACE2 inhibition to ancestral RBD and 38-RBD variants. (A) Pan-IgG binding levels (reciprocal ED₅₀) and (B) human wild-type ACE2 (hACE2) inhibition levels (reciprocal ID_{50}) by BNT162b2 (two-weeks following second dose; blue; n =16) and mild/moderate convalescent COVID-19 patients (green; median 38 days post symptom onset; n = 15) as measured by multiplex to RBD variants. Reciprocal ED₅₀/ID₅₀ values respectively were calculated using the normalized binding MFI-value for an 8-point serial plasma titration. (C) Fold change of pan-IgG binding levels of RBD variants in comparison to ancestral-RBD and (D) Fold change of hACE2 inhibition of RBD variants in comparison to ancestral-RBD by BNT162b2 plasma. Fold change was calculated as follows: (geometric mean of reciprocal ED₅₀ or ID₅₀ Ancestral-RBD) divided by (geometric mean reciprocal ED₅₀ or ID₅₀ variant-RBD). Friedman's non-parametric test with Dunn's multiple comparisons was used to assess statistical significance. (E) Pan-IgG binding levels (reciprocal ED₅₀) and (F) hACE2 inhibition levels (reciprocal ID₅₀) to RBD of Omicron BA.2 variant with fold-change as indicated above in blue. Mann-Whitney U-test used for statistical evaluation. p < 0.05 (*), p <0.01 (**), p < 0.001 (***)and p < 0.0001 (****).Figure 3. Affinity of wild-type (WT) hACE2 to the RBD of variants. Sensograms of WT-human ACE2 (hACE2) binding affinity to (A) ancestral-RBD, (B) Alpha (B.1.1.7), (C) Beta (B.1.351), (D) Delta (B.1.617.2) (E) Gamma (P1), (F) Omicron (BA.2) as

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

measured by biolayer interferometry (BLI). Binding of 2-fold serial dilutions of each SARS-CoV-2 RBD variant (100 nM (red), 50 nM (yellow), 25 nM (green), 12 nM (blue), and 6 nM (pink)) was measured to immobilised hACE2 (3ug/ml). Binding curves representative of 2 independent experiments for each variant are plotted (solid-colored lines), globally fitted to a 1:1 binding model (black line). Figure 4. Affinity of hACE2 polymorphisms to VOC RBD's. Binding profiles of WT hACE2 (purple) and three polymorphisms (E35K, green; K26R, red; S19P, blue) to (A) ancestral-RBD and RBD of variants of concern (B) Alpha (B.1.1.7), (C) Beta (B.1.351), (D) Delta (B.1.617.2), (E) Omicron (BA.2). Sensograms show 100 nM of immobilised RBD of each variant run against 100nm (3ug/ml) ACE2 of each polymorphism to measure binding kinetics. Figure 5. Loss of anti-RBD FcyR-binding antibodies and ADCP responses to VOC RBDs in BNT162b2 and convalescent plasma (A) FcyRIIa-H131 and (B) FcyRIIIa-V158 binding levels of RBD-specific antibodies using plasma of BNT162b2 (two-weeks following second dose; blue; n = 16) and mild/moderate convalescent COVID-19 patients (green; median 38 days post symptom onset; n = 15) as measured via multiplexing. (C) Fold change of anti-RBD FcyRIIa-H131 binding levels to RBD-variants in comparison to ancestral-RBD of BNT162b2 plasma. (D) Fold change of FcyRIIIa-V158 levels of RBD variants in comparison to ancestral of BNT162b2 plasma. Reciprocal ED₅₀ values were calculated using the normalized FcyR binding MFI-value for an 8-point serial plasma titration. Fold change was calculated as follows: (geometric mean of reciprocal ED₅₀ or ID₅₀ respectively ancestral-RBD) divided by (geometric mean reciprocal ED₅₀ or ID₅₀ respectively variant-RBD). Friedman's non-parametric test with Dunn's multiple

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

comparisons was used to assess statistical significance. (E) Pan-IgG binding (Reciprocal ED50) and (F) hACE2 inhibition levels to RBD of Omicron variant with fold-change of BNT162b2 plasma indicated above in blue. Mann-Whitney U-test used to assess statistical significance. (G-H) Spearman correlations of phagocytosis activity (reciprocal ED50) using THP-1 monocytes and multiplex FcRIIa-H131 data (reciprocal ED50) against the ancestral and Beta RBD. (I) ADCP by THP-1 monocytes induced by the plasma of BNT162b2 against the ancestral and Beta RBD shown as phagocytic score ED50s. Wilcoxon matched pairs signed rank test was used to assess statistical significance. p < 0.05 (*), p < 0.01 (***), p < 0.001 (***) and p < 0.0001 (****) **Supplementary Figure Legends** Supplementary Figure 1. Schematic representation of duplex phagocytosis assay and gating strategy. (A) Schematic of the antibody dependent phagocytosis (ADCP) duplex assay. Briefly, APC fluorescent beads coated with ancestral RBD, while FITC fluorescent beads coated with RBD Beta were added to wells and incubated with plasma for 2 hours at 37°C. Following incubation, THP-1 monocytes were added to wells and incubated with opsonised beads for 2 hours under cell culture conditions before fixing cells for flow cytometry. (B) Representative gating strategy using pooled 2-week post vaccination plasma (blue), pooled baseline plasma (red) and no plasma (grey). Gating was performed by gating on THP-1 monocytes, single cells and finally cells positive for RBDWT beads and RBD Beta beads. (C) Visualisation of single and double bead positive cells as dot plots for representative samples. Supplementary Figure 2. IgG subclass recognition of SARS-CoV-2 antigens and correlations to FcyR engagement.

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

Plasma antibody isotype response (pan IgG, IgA1, IgM) (A-C), IgG subclass responses (IgG1, IgG2, IgG3 IgG4) (D-G) and Fc\(\gamma\)R engagement (Fc\(\gamma\)R3av and Fc\(\gamma\)R2aH) (H-I) to NP, RBD, S1 and spike trimer were profiled via multiplex. Convalescent mild/moderate COVID-19 patients (green square; median 38 days post symptom onset; n = 15) and BNT162b2-vaccinated individuals at baseline (purple triangle; n = 16) and two-weeks following second dose (blue circle; n = 16) were assessed. (J) Pearson R correlation matrix of IgG subclass binding (IgG1, IgG2, IgG3, IgG4) and FcγR engagement (FcγR3av and FcγR2aH) with R values in bold and P-values described in italics. Supplementary Figure 3. Affinity of wild-type (WT) hACE2 to the RBD mutations. Sensograms of WT-human ACE2 (hACE2) binding affinity to (A) K417N, (B) K417T, (C) G446S, (D) L452R (E) L452R E484Q, (F) Y453F, (G) S477N, (H) T478K, (I) E484D, (J) E484K and (K) 484Q, (L) S494P and (M) N501T as measured by biolayer interferometry (BLI). Binding of 2-fold serial dilutions of each SARS-CoV-2 RBD variant (100 nM (red), 50 nM (yellow), 25 nM (green), 12 nM (blue), and 6 nM (pink)) was measured to immobilised hACE2 (3ug/ml). Binding curves representative of 2 independent experiments for each variant are plotted (solid-colored lines), globally fitted to a 1:1 binding model (black line). Supplementary Table 1. Antigens used in SARS-CoV-2-specific array **Supplementary Table 2. RBD recombinant proteins (variants and single point mutations)** used in RBD array

Supplementary Table 3. Friedmans Test using Dunn's multiple comparisons statistical values for comparison of IgG-binding, ACE2-inhibition, FcRIIa-binding and FcRIIIabinding of RBD-variants to ancestral RBD Supplementary Table 4. Affinity constants of wild-type (WT) hACE2 to RBD with single point mutations. Measured via BLI, calculated from 2 independent experiments Supplementary Table 5. Affinity of human ACE2 polymorphisms to SARS-CoV-2 RBD Variants. Measured via BLI, calculated from 2 independent experiments Supplementary Figure 6. Frequency of human ACE2 polymorphisms (E35K, K26R, S19P) found within human populations. Polymorphism data collated from Genome Aggregation Database (gnomAD; https://gnomad.broadinstitute.org)

695 References

- Magazine N, Zhang T, Wu Y, McGee MC, Veggiani G, Huang W. Mutations and
 Evolution of the SARS-CoV-2 Spike Protein. Viruses 2022, Vol 14, Page 640 [Internet].
 2022 Mar 19 [cited 2022 Jun 1];14(3):640. Available from:
 https://www.mdpi.com/1999-4915/14/3/640/htm
- Mannar D, Saville JW, Zhu X, Srivastava SS, Berezuk AM, Zhou S, et al. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Reports [Internet]. 2021 Dec 21 [cited 2022 May 27];37(12):110156. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2211124721016521
- Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells.
 Nature Reviews Molecular Cell Biology 2021 23:1 [Internet]. 2021 Oct 5 [cited 2022 Jun 1];23(1):3–20. Available from: https://www.nature.com/articles/s41580-021-00418-x
- 709 4. Tian F, Tong B, Sun L, Shi S, Zheng B, Wang Z, et al. N501y mutation of spike protein in sars-cov-2 strengthens its binding to receptor ace2. Elife. 2021 Aug 1;10.
- Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine 2021 27:7 [Internet]. 2021 May 17 [cited 2022 Jun 1];27(7):1205–11. Available from: https://www.nature.com/articles/s41591-021-01377-8
- 716 6. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection 717 against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine 2021 718 27:11 [Internet]. 2021 Sep 29 [cited 2022 Jun 1];27(11):2032–40. Available from: 719 https://www.nature.com/articles/s41591-021-01540-1
- Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
 Nature Medicine 2021 27:5 [Internet]. 2021 Mar 26 [cited 2022 Jun 1];27(5):917–24.
 Available from: https://www.nature.com/articles/s41591-021-01318-5
- Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al.
 Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 2021
 602:7898 [Internet]. 2021 Dec 23 [cited 2022 Jun 1];602(7898):671–5. Available from:
 https://www.nature.com/articles/s41586-021-04389-z
- Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al.
 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature
 2021 596:7871 [Internet]. 2021 Jul 8 [cited 2022 Jun 1];596(7871):276–80. Available
 from: https://www.nature.com/articles/s41586-021-03777-9
- Alter G, Yu J, Liu J, Chandrashekar A, Borducchi EN, Tostanoski LH, et al.
 Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
 Nature 2021 596:7871 [Internet]. 2021 Jun 9 [cited 2022 Jun 1];596(7871):268–72.
 Available from: https://www.nature.com/articles/s41586-021-03681-2
- Jangra S, Ye C, Rathnasinghe R, Stadlbauer D, Alshammary H, Amoako AA, et al. SARS CoV-2 spike E484K mutation reduces antibody neutralisation. The Lancet Microbe
 [Internet]. 2021 Jul 1 [cited 2022 Jun 1];2(7):e283–4. Available from:
- 739 http://www.thelancet.com/article/S2666524721000689/fulltext

- Yu J, Collier A ris Y, Rowe M, Mardas F, Ventura JD, Wan H, et al. Neutralization of the
 SARS-CoV-2 Omicron BA.1 and BA.2 Variants. New England Journal of Medicine
 [Internet]. 2022 Apr 21 [cited 2022 Jun 30];386(16):1579–80. Available from:
 https://www.nejm.org/doi/full/10.1056/NEJMc2201849
- 744 13. Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, et al. Markers of
 745 Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. 2021 [cited 2022 Jun
 746 1]; Available from: https://doi.org/10.1128/mBio
- 14. Lee WS, Selva KJ, Davis SK, Wines BD, Reynaldi A, Esterbauer R, et al. Decay of Fc dependent antibody functions after mild to moderate COVID-19. Cell Reports
 Medicine. 2021 Jun 15;2(6):100296.
- 750 15. Yamin R, Jones AT, Hoffmann HH, Schäfer A, Kao KS, Francis RL, et al. Fc-engineered 751 antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 2021 599:7885 752 [Internet]. 2021 Sep 21 [cited 2022 Jun 1];599(7885):465–70. Available from: 753 https://www.nature.com/articles/s41586-021-04017-w
- Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, et al. Antibody
 potency, effector function, and combinations in protection and therapy for SARS-cov 2 infection in vivo. Journal of Experimental Medicine [Internet]. 2020 Mar 1 [cited
 2022 Jun 1];218(3). Available from: https://doi.org/10.1084/jem.20201993
- Tauzin A, Nayrac M, Benlarbi M, Gong SY, Gasser R, Beaudoin-Bussières G, et al. A
 single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody
 effector functions and T cell responses. Cell Host & Microbe. 2021 Jul 14;29(7):1137 1150.e6.
- 762 18. Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Chong Z, et al. Human neutralizing
 763 antibodies against SARS-CoV-2 require intact Fc effector functions for optimal
 764 therapeutic protection. Cell. 2021 Apr 1;184(7):1804-1820.e16.
- 765 19. Daëron M. Fc RECEPTOR BIOLOGY.
- 766 http://dx.doi.org/101146/annurev.immunol151203 [Internet]. 2003 Nov 28 [cited 2022 Jun 1];15:203–34. Available from:
- 768 https://www.annualreviews.org/doi/abs/10.1146/annurev.immunol.15.1.203
- Chan CEZ, Seah SGK, Chye DH, Massey S, Torres M, Lim APC, et al. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody. PLOS ONE [Internet]. 2021 Jun 1 [cited 2021 Oct 7];16(6):e0253487. Available from:
- 774 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253487
- Singh H, Choudhari R, Nema V, Khan AA. ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease. Microbial Pathogenesis [Internet]. 2021 Jan 1 [cited 2022 May 27];150:104621. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0882401020309876
- 779 22. Bosso M, Thanaraj TA, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The Two
 780 Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and
 781 COVID-19. Molecular Therapy Methods & Clinical Development [Internet]. 2020 Sep
 782 11 [cited 2022 May 27];18:321–7. Available from:
- 783 https://linkinghub.elsevier.com/retrieve/pii/S2329050120301418
- 784 23. Stawiski EW, Diwanji D, Suryamohan K, Gupta R, Fellouse FA, Sathirapongsasuti JF, et 785 al. Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility. bioRxiv

- 786 [Internet]. 2020 Apr 10 [cited 2022 May 28];2020.04.07.024752. Available from: https://www.biorxiv.org/content/10.1101/2020.04.07.024752v1
- Suryamohan K, Diwanji D, Stawiski EW, Gupta R, Miersch S, Liu J, et al. Human ACE2
 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Communications
 Biology 2021 4:1 [Internet]. 2021 Apr 12 [cited 2022 May 27];4(1):1–11. Available
 from: https://www.nature.com/articles/s42003-021-02030-3
- Calcagnile M, Forgez P, Iannelli A, Bucci C, Alifano M, Alifano P. Molecular docking
 simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with
 the SARS-CoV-2 Spike protein. Biochimie [Internet]. 2021 Jan 1 [cited 2022 May
 27];180:143–8. Available from:
 https://linkinghub.elsevier.com/retrieve/pii/S0300908420302820
- Barton MI, Macgowan S, Kutuzov M, Dushek O, Barton GJ, Anton Van Der Merwe P.
 Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human
 ACE2 receptor on binding affinity and kinetics. Elife [Internet]. 2021 Aug 1 [cited 2022
 Jun 1];10. Available from: /pmc/articles/PMC8480977/
- Juno JA, Tan HX, Lee WS, Reynaldi A, Kelly HG, Wragg K, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nature
 Medicine 2020 26:9 [Internet]. 2020 Jul 13 [cited 2021 Sep 22];26(9):1428–34.
 Available from: https://www.nature.com/articles/s41591-020-0995-0
- Selva KJ, Davis SK, Haycroft ER, Lee WS, Lopez E, Reynaldi A, et al. Tear antibodies to
 SARS-CoV-2: implications for transmission. Clinical & Translational Immunology
 [Internet]. 2021 Jan 1 [cited 2022 Apr 20];10(11):e1354. Available from:
 https://onlinelibrary.wiley.com/doi/full/10.1002/cti2.1354
- Wheatley AK, Pymm P, Esterbauer R, Dietrich MH, Lee WS, Drew D, et al. Landscape
 of human antibody recognition of the SARS-CoV-2 receptor binding domain. Cell
 Reports. 2021 Oct 12;37(2):109822.
- 30. Lopez E, Haycroft ER, Adair A, Mordant FL, O'Neill MT, Pymm P, et al. Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight [Internet]. 2021 Aug 23 [cited 2022 Mar 11];6(16). Available from: /pmc/articles/PMC8409985/
- Selva KJ, van de Sandt CE, Lemke MM, Lee CY, Shoffner SK, Chua BY, et al. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nature Communications 2021 12:1 [Internet]. 2021 Apr 1 [cited 2021 Sep 23];12(1):1–14. Available from: https://www.nature.com/articles/s41467-021-22236-7
- 32. McLean MR, Madhavi V, Wines BD, Hogarth PM, Chung AW, Kent SJ. Dimeric Fcγ
 Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A
 New Look into Breadth of Fcγ Receptor Antibodies Induced by the RV144 Vaccine
 Trial. The Journal of Immunology [Internet]. 2017 Jul 15 [cited 2022 Jun
 1];199(2):816–26. Available from: https://www.jimmunol.org/content/199/2/816
- 33. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods [Internet]. 2011 Mar 7 [cited 2021 Nov 22];366(1–2):8. Available from: /pmc/articles/PMC3050993/
- 830 34. Butler AL, Fallon JK, Alter G. A sample-sparing multiplexed ADCP assay. Frontiers in Immunology [Internet]. 2019 Aug 13 [cited 2021 Jun 30];10(AUG):1851. Available from: www.frontiersin.org

- 833 35. Darrah PA, Patel DT, de Luca PM, Lindsay RWB, Davey DF, Flynn BJ, et al.
- 834 Multifunctional TH1 cells define a correlate of vaccine-mediated protection against
- Leishmania major. Nature Medicine 2007 13:7 [Internet]. 2007 Jun 10 [cited 2022 May 4];13(7):843–50. Available from: https://www.nature.com/articles/nm1592
- 837 36. Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK, Dunphy LJ, et al. Dissecting 838 Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology. 839 Cell. 2015 Nov 5;163(4):988–98.
- S40 37. Chakraborty S. E484K and N501Y SARS-CoV 2 Spike Mutants Increase ACE2
 Recognition but Reduce Affinity for Neutralizing Antibody. International
 Immunopharmacology [Internet]. 2022 Jan 1 [cited 2022 May 27];102. Available
 from: /pmc/articles/PMC8641390/
- 38. Ozono S, Zhang Y, Ode H, Sano K, Tan TS, Imai K, et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nature Communications 2021 12:1 [Internet]. 2021 Feb 8 [cited 2022 May 27];12(1):1–9. Available from: https://www.nature.com/articles/s41467-021-21118-2
- Wu L, Zhou L, Mo M, Liu T, Wu C, Gong C, et al. SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2.
 Signal Transduction and Targeted Therapy 2022 7:1 [Internet]. 2022 Jan 5 [cited 2022 Jun 1];7(1):1–3. Available from: https://www.nature.com/articles/s41392-021-00863-2
- 40. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS 854 CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol [Internet].
 855 2021 Jun 1 [cited 2021 Jun 7];1–16. Available from:
 856 http://www.ncbi.nlm.nih.gov/pubmed/34075212
- Davis C, Logan N, Tyson G, Orton R, Harvey WT, Perkins JS, et al. Reduced
 neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following
 vaccination. PLOS Pathogens [Internet]. 2021 Dec 1 [cited 2022 Feb
 25];17(12):e1010022. Available from:
 https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1010022
- Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. AZD1222-induced
 neutralising antibody activity against SARS-CoV-2 Delta VOC. The Lancet [Internet].
 2021 Jun [cited 2021 Jul 5]; Available from:
- https://linkinghub.elsevier.com/retrieve/pii/S0140673621014628
- 43. Garcia-Beltran WF, Lam EC, st. Denis K, Nitido AD, Garcia ZH, Hauser BM, et al.
 Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;
- 869 44. Bartsch YC, Tong X, Kang J, Avendaño MJ, Serrano EF, García-Salum T, et al. Omicron 870 variant Spike-specific antibody binding and Fc activity are preserved in recipients of 871 mRNA or inactivated COVID-19 vaccines. Science Translational Medicine [Internet]. 872 2022 Mar 15 [cited 2022 Jun 1];14:9243. Available from:
- https://www.science.org/doi/full/10.1126/scitranslmed.abn9243
- 45. Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.
- 876 Cell Discovery 2020 6:1 [Internet]. 2020 Feb 24 [cited 2022 Jun 1];6(1):1–4. Available
- 877 from: https://www.nature.com/articles/s41421-020-0147-1

- Ali F, Elserafy M, Alkordi MH, Amin M. ACE2 coding variants in different populations
 and their potential impact on SARS-CoV-2 binding affinity. Biochemistry and
 Biophysics Reports. 2020 Dec 1;24:100798.
- Chen F, Zhang Y, Li X, Li W, Liu X, Xue X. The Impact of ACE2 Polymorphisms on
 COVID-19 Disease: Susceptibility, Severity, and Therapy. Frontiers in Cellular and
 Infection Microbiology. 2021 Oct 22;11:1002.
- 48. Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, et al. SARS-CoV-2
 spike L452R variant evades cellular immunity and increases infectivity. Cell Host &
 Microbe. 2021 Jul 14;29(7):1124-1136.e11.
- 49. Pickering B, Lung O, Maguire F, Kruczkiewicz P, Kotwa JD, Buchanan T, et al. Highly divergent white-tailed deer SARS-CoV-2 with potential deer-to-human transmission.
 bioRxiv [Internet]. 2022 May 24 [cited 2022 Jun 1];2022.02.22.481551. Available from: https://www.biorxiv.org/content/10.1101/2022.02.22.481551v3
- Kutter JS, de Meulder D, Bestebroer TM, Lexmond P, Mulders A, Richard M, et al.
 SARS-CoV and SARS-CoV-2 are transmitted through the air between ferrets over more
 than one meter distance. Nature Communications 2021 12:1 [Internet]. 2021 Mar 12
 [cited 2022 Jun 1];12(1):1–8. Available from:
 https://www.nature.com/articles/s41467-021-21918-6
- 896 51. Richard M, Kok A, de Meulder D, Bestebroer TM, Lamers MM, Okba NMA, et al. SARS-897 CoV-2 is transmitted via contact and via the air between ferrets. Nature 898 Communications 2020 11:1 [Internet]. 2020 Jul 8 [cited 2022 Jun 1];11(1):1–6. 899 Available from: https://www.nature.com/articles/s41467-020-17367-2
- 52. Koutsakos M, Lee WS, Reynaldi A, Tan HX, Gare G, Kinsella P, et al. The magnitude
 901 and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV 902 2 variants. Immunity [Internet]. 2022 May [cited 2022 Jun 1];0(0). Available from:
 903 http://www.cell.com/article/S1074761322002382/fulltext

905

906

911

907 SELVA, K. J., VAN DE SANDT, C. E., LEMKE, M. M., LEE, C. Y., SHOFFNER, S. K., CHUA, B. Y., 908 DAVIS, S. K., NGUYEN, T. H., ROWNTREE, L. C. & HENSEN, L. 2021. Systems serology 909 detects functionally distinct coronavirus antibody features in children and elderly. 910 Nature communications, 12, 1-14.

Table 1: Cohort Demographics

	Baseline (n = 16)	BNT162b2 recipients	COVID-19 Patients (n = 15)
Age, median (IQR), years	30.5 [5.5]	(n = 16) 30.5 [5.5]	49 [23]
Gender			
Female, n(%)	10 (62.5%)	10 (62.5%)	9 (60%)
Male, n(%)	6 (37.5%)	6 (37.5%)	6 (40%)
Days from symptom onset, median (IQR)			38 [10.5]
Severity			
Mild, n(%)			9 (60%)
Moderate, n(%)			6 (40%)
BNT162b2-vaccine			
Days since second dose, median (IQR)		13 [0.75]	

^{*} Mild defined as upper respiratory tract symptoms only; Moderate defined as including lower respiratory track symptoms. All patients non-hospitalised




Figure 1.




Figure 2




Figure 3




Figure 4




Figure 5